Malgorzata Jaremko, Phd, Facmg, Facb, Mba, Msc, Eng Email & Phone Number

New York, Ny, Us

Kearny, New Jersey, Us

Dallas, Texas, Us

My start-up company: Gosia Genomics participated in and graduated from the Health Wildcatters accelerator program.

New York, Us

New York, Ny, Us

North Brunswick, New Jersey, Us

Secaucus, Nj, Us

Secaucus, Nj, Us

Secaucus, Nj, Us

New York, Ny, Us

Department of Genetics & Genomics Sciences• Initiated, developed and conducted project on personalization of Tamoxifen therapy based on genetic testing and therapeutic monitoring of Tamoxifen and its active metabolites• As a first developed and reported LC-MS/MS based method to therapeutic monitoring of Tamoxifen and its metabolites, including number of their hydroxylated isomers having strong clinical implications (Anal Chem 2010; 82:10186-93). Additionally, performed analytical and clinical validation of this methodology and was responsible for preparation of all the documents for the submission of an application to the New York State Department of Health for approval of this assay for diagnostic use. • Designed and conducted clinical trial on Tamoxifen dose adjustment based on patient’s CYP2D6 genotype and levels of Tamoxifen and Tamoxifen’s active metabolites. As a first showed that therapeutic level of metabolically active form- Endoxifen can be achieved even in patients with a poor metabolizing phenotype by standard dose increase of only 10 mg/day (Clin Pharm & Therapeutics. 2011; 90: 605-11). • Performed CYP2C9 and VKORC1 genotyping of patients with various Warfarin doses to establish/confirm impact of polymorphisms in these genes on the achieving therapeutic range.• Determined new genetics variants in CYP2C9 and VKORC1 across different population and their impact on performance of existing Warfarin treatment algorithms (Pharmacogenomics. 2009; 10: 1243-55)• Compared published gene based Warfarin dosing algorithms in a racially diverse, multiethnic population to improve efficacy and reduce adverse effects that occur during traditional anticoagulant therapy guided only by clinical variables (J Thromb Haemost. 2010; 8:1018-26).

New York, Ny, Us

• Clinical and laboratory training biochemical genetics and diagnosis of inherited metabolic disorders using i.e.: quantitative amino acids analysis by Biochrom, LC-MS/MS; organic acids profiling in urine by GC- MS; carnitine and acylcarnitinine analysis by LC-MS/MS; Phorphyria by LC-MS/MS; fluorometric enzyme assays for Fabry, Gaucher and Tay- Sachs diseases etc.• Daily responsibility included biochemical testing and resolution of clinical cases: 1) Preparation of the sample for analysis, 2) Performing analytical testing of the sample: programming and running of the instruments, chromatographic baseline review, mass spec and chromatography peak identification, performance of manual assays. 3). Interpretation of test results: interpretation of mass spectrometry profiles and patterns, evaluation of the clinical significance of findings, gathering additional clinical and/or laboratory data, generating a differential diagnosis, recommending further testing, and generating a draft and final version of the written report, 4) Communication of results to health care providers or ordering physicians.• SOP preparation and verification, QC monitoring, proficiency testing, laboratory equipment monitoring, laboratory management, trouble-shooting and problem solving with assays and instrumentation.• Responsible for development of new mass spectrometry methods for therapeutic drug monitoring (Tamoxifen, Warfarin).• Performed analytical and clinical validation of LC-MS/MS methodologies for NY State Department of Health approval, and accomplished integration of the NY State approved assays into the clinical work flow.•Experienced in the preparation of the laboratory for NY State and CAP inspections.

New York, Ny, Us

• Clinical and laboratory training in molecular diagnostics of genetic disorders and syndromes i.e. Noonan Syndrome, Fragile-X, Cystic Fibrosis, Roberts Syndrome, Y-microdeletion, panel of Ashkenazi Jewish diseases (i.e.Tay-Sachs Disease, Gaucher Disease, Bloom syndrome, Canvan Disease, Mucolipidosis type IV, Niemann-Pick Disease, Fanconi Anemia Group C, Familial Dysautonomia, Maple Syrup Urine Disease) using wide spectra of molecular technologies including Luminex system, Sanger sequencing, Southern blot, RFLP, DHPLC, FRET assays, MLPA • Responsible for validation of new and routine performance of existing clinical pharmacogenetics testing of: CYP2C9, VKORC1, CYP2D6, CYP2C19 genes.• Daily responsibility included molecular testing and resolution of clinical cases: 1) Preparation of the sample for analysis- DNA extraction, 2) Performing analytical testing of the samples: programming and running of the instruments, and testing results analysis, 3) Interpretation of results: evaluation of the clinical significance of findings, gathering additional clinical and/or laboratory data, generating a differential diagnosis, recommending further testing, and generating a draft and final version of the written report, 4) Communication of results to the health care providers or ordering physicians• Responsible for development of new testing methodologies, assay’s validations, SOP writing and preparation of submission packets of the new genetic tests for New York State Department of Health approval• Involved in the overall laboratory administration and monitoring of QA systems

Lower Silesian, Pl

Rotterdam, Zuid-Holland, Nl

Fellow of the European Science Foundation, recipient of Integrated Approaches for Functional Genomics grant to perform project on "Identification of functional pathways associated with clinical chemotherapy-resistance in breast cancer by advanced mass spectrometry"• Established peptides profile of the chemotherapy response and resistance in breast cancer patient by MALDI-TOF MS and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS) (Expert Rev. Proteomics 2008; 5: 445-55)• Developed and applied MALDI-TOF, FTICR-MS, LC-MS/MS, Laser Capture Microdissection and other histological procedures to investigate markers for personalized breast cancer treatment.

Ph.D. Marie Curie Fellowship from the 5th Framework of the European Union Program “Fighting Breast Cancer” and Ph.D. Fellowship from Robert Bosch Foundation for Medical Research in GermanyPerformed Ph.D. study research on personalized breast cancer chemotherapy:• Completed extensive training in breast cancer pharmacogenetics, cancer pathogenesis, therapy response, and implications of CYP450 enzymes polymorphisms in the drugs metabolism, as well as on genotyping methodologies using Real-time PCR (Applied Biosystems) and MALDI-TOF MS. Additionally obtained training on immunohistochemistry techniques.• Performed research that lead to establishing one of the first application of DNA extracted from archival paraffin-embedded tissues to the genotyping by MALDI-TOF MS and TaqMan Allelic Discrimination and its assessment in the pharmacogenetics studies (Hum Mut 2005; 25:232-238) • Performed pharmacogenetics association study on breast cancer chemotherapy (CMF/ anthracyclines) outcome and polymorphisms in genes encoding drug metabolizing enzymes, cell cycle and apoptosis regulators, and revealed an impact of DNA repair enzymes polymorphisms on therapy outcome (Pharmacogenet. Genomics 2007; 17:529-38)

Clinical Fellowship In Clinical Molecular & Biochemical Genetics

Clinical Fellowship In Clinical Cytogenetics

Master Of Business Administration - Mba

Postgraduate Degree, Molecular Medicine

Postgraduate Degree, Journalism

Doctor Of Philosophy - Phd, Molecular Biology

Master Of Engineering - Meng; Master Of Science